Condition
Cryopyrin-associated Periodic Syndromes (CAPS)
Total Trials
4
Recruiting
2
Active
2
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
50% success
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 2 (1)
Trial Status
Recruiting2
Terminated1
Completed1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07247266Phase 1RecruitingPrimary
Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of JTE-162 in Subjects With Cryopyrin-Associated Periodic Syndrome (CAPS)
NCT06838143Recruiting
Ilaris NIS in Korea
NCT02853084Phase 2TerminatedPrimary
HL2351 CAPS Phase II Study
NCT01213641CompletedPrimary
Clinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) Patients
Showing all 4 trials